MedCity News

Obsidian, Galera Merger Comes With $350M Infusion for Cancer Drug Trials

Obsidian Therapeutics is merging with Galera Therapeutics to advance clinical development of a pipeline led by a next-generation cell therapy for melanoma that could offer advantages over the only ...
Fierce Biotech

UCB inks $2B Candid buyout to join Gilead in autoimmune field

UCB has struck a deal to acquire Candid Therapeutics for $2 billion upfront, hijacking a planned reverse merger with Rallybio ...
Seeking Alpha

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

PHILADELPHIA and MALVERN, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Carisma Therapeutics Inc. (CARM) (Carisma) and OrthoCellix, Inc. (OrthoCellix), a wholly-owned subsidiary of Ocugen, Inc. (Ocugen), a ...
Nasdaq

Carisma Therapeutics and OrthoCellix Announce Proposed Reverse Merger to Form Nasdaq-Listed Regenerative Cell Therapy Company

Carisma Therapeutics Inc. and OrthoCellix, a subsidiary of Ocugen, have announced a definitive merger agreement to create a Nasdaq-listed regenerative cell therapy company. The merger, which will be ...
Nasdaq

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

PHILADELPHIA and MALVERN, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Carisma Therapeutics Inc. (Nasdaq: CARM) (Carisma) and OrthoCellix, Inc. (OrthoCellix), a wholly ...